First approved for adults in 2022, the therapy is now cleared for adults and pediatric patients weighing 66 lbs or more with symptomatic obstructive hypertrophic cardiomyopathy.
News|Articles|February 18, 2019
Cablivi for Acquired Thrombotic Thrombocytopenic purpura
Author(s)Drew Boxler
What you need to know about the von Willebrand factor (vWF)-directed antibody fragment.
Advertisement
Cablivi (caplacizumab-yhdp, Sanofi Genzyme)
Indications: Treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy
Dosage:
- Day 1 of treatment: 11-mg bolus intravenous injection at least 15 min prior to plasma exchange, followed by 11-mg subcutaneous injection after plasma exchange
- 11-mg subcutaneous injection once daily for 30 days following plasma exchange
- Treatment may be extended for a maximun of 28 days only if persistent underlying diseases remain present
- Discontinue if two or more recurrences of aTTP occur while on Cablivi
Contraindications: Previous severe hypersensitivity reaction to caplacizumab-yhdp or any of the excipients.
Advertisement
Related to this article
The update adds efficacy and safety data on adults newly diagnosed with pulmonary arterial hypertension.
Researchers outline individual peripheral arterial disease burden as well as the most at-risk patient populations and treatment recommendations.
Study findings tie continuous glucose monitoring measures to elevated cardiovascular risk in adults without diabetes.
The once daily tablet is expected to reach US patients in October 2026.
The label expansion adds patients 12 years of age and older to the once daily alopecia areata indication.
An American Heart Association scientific statement shows earlier risk factors and social barriers driving cardiovascular disparities in Hispanic adults.
This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.
Advertisement
Advertisement
Trending on Drug Topics
1
What Is HIV PrEP and Who Needs It Most?
2
Indirect Comparison Links Tirzepatide to Greater Weight Loss Than Semaglutide
3
Infections Fall With Azithromycin for Unscheduled Cesarean Deliveries
4
Pharmacists Are Vital in Complex, Team-Based Treatment of PAD
5